Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of insulin-treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion, which restores normal plasma glucose levels by stimulation of hepatic glucose production. This counterregulatory mechanism is impaired in diabetes. Here we show in mice that therapeutic concentrations of insulin inhibit glucagon secretion by an indirect (paracrine) mechanism mediated by stimulation of intra-islet somatostatin release. Insulin's capacity to inhibit glucagon secretion is lost following genetic ablation of insulin receptors in the somatostatin-secreting δ-cells, when insulin-induced somatostatin secretion is suppressed by dapagliflozin (an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists. Administration of these compounds in vivo antagonises insulin's hypoglycaemic effect. We extend these data to isolated human islets. We propose that SSTR or SGLT2 antagonists should be considered as adjuncts to insulin in diabetes therapy.

Original publication

DOI

10.1038/s41467-018-08193-8

Type

Journal article

Journal

Nat Commun

Publication Date

11/01/2019

Volume

10

Keywords

Animals, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Female, Glucagon, Glucagon-Secreting Cells, Glucosides, Humans, Hypoglycemia, Insulin, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Receptor, Insulin, Receptors, Somatostatin, Sodium-Glucose Transporter 2, Sodium-Glucose Transporter 2 Inhibitors, Somatostatin